
AZ reveals compelling PhIII data for ovarian cancer treatment
pharmafile | October 26, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AZ, AstraZeneca, lynparza
AstraZeneca has revealed new results from a Phase III trial investigating the efficacy of its Lynparza drug as a monotherapy for the treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.
The results showed that the drug achieved a statistically significant improvement of progression-free survival (PFS) in patients compared to placebo. Median PFS also substantially exceeded what the drug recorded in its Phase II trial studying patients with platinum-sensitive relapsed ovarian cancer. Safety findings remained consistent with earlier data.
The results follow the FDA’s decision to award Lynparza Fast Track Designation earlier this year.
“We are pleased with the robust improvement in progression-free survival demonstrated by Lynparza in the SOLO-2 trial,” commented Sean Bohen, executive VP of Global Medicines Development and CMO at AstraZeneca. “We will work with regulatory authorities to make Lynparza tablets available as quickly as possible to patients with ovarian cancer. We remain committed to investigating the full potential of Lynparza, both as monotherapy and in combinations, and to identifying all patients who may benefit from this important medicine.”
Matt Fellows
Related Content

AstraZeneca’s Trixeo approved in EU for asthma
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a …

NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …






